Diamyd Medical AB (publ) (FRA:DMN)

Germany flag Germany · Delayed Price · Currency is EUR
0.0617
-0.0147 (-19.24%)
Last updated: Apr 24, 2026, 8:04 AM CET
Market Cap15.32M -80.9%
Revenue (ttm)33.96K +98.9%
Net Income-18.80M
EPS-0.15
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume3,337
Open0.0617
Previous Close0.0764
Day's Range0.0617 - 0.0617
52-Week Range0.0617 - 1.8000
Betan/a
RSI26.00
Earnings DateJun 24, 2026

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 41
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DMN

Financial Performance

In fiscal year 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.

Financial numbers in SEK Financial Statements